Therapeutic Response

PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Pembrolizumab in patients with Cervical Adenocarcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS >=1), as determined by an FDA-approved test.
Pembrolizumab 400mg Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.
Pembrolizumab 200mg Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg and 400mg) for reimbursement as a monotherapy treatment option for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 with a CPS >= 1. Pembrolizumab (200mg) monotherapy's regime notes that this indication is an unlicensed dosing posology of pembrolizumab in Ireland, and that patients should be informed of this and consented to treatment in line with the hospital's policy on the use of unlicensed medication and unlicensed or 'off-label' indications. Please refer to this therapy's regime by the HSE for more information.